NanoPin TB Assay
Tuberculosis (Active Disease Detection)
Commercial (LDT)Active
Key Facts
Indication
Tuberculosis (Active Disease Detection)
Phase
Commercial (LDT)
Status
Active
Company
About NanoPin Technologies
NanoPin Technologies, founded in 2017 and headquartered in San Diego, is a private diagnostics company pioneering a nanoparticle-based platform for infectious disease detection. Its core innovation involves proprietary antibody-conjugated nanoparticles that bind to disease-specific antigen peptides present only during active infection, enabling sensitive blood-based diagnosis. The company's lead efforts target the global tuberculosis epidemic, with assays also developed for HIV and COVID-19, and it has established a key collaboration with Thermo Fisher Scientific. NanoPin operates in the Laboratory Developed Test (LDT) market while advancing its platform for broader applications.
View full company profile